Bruce Bloom, President of Cures Within Reach, spoke in the 'Alternative funding strategies' panel at the Cambridge Rare Disease Summit 2015.

1. Alternative Financing Strategies
Dr. Bruce E. Bloom
President and Chief Science Officer
Cures Within Reach

2. Cures Within Reach is a global non-profit organization dedicated to
improving patient quality and length of life through Repurposing
Research, creating new treatments using existing drugs and devices.
Our three goals are:
• To raise awareness of repurposing as a medical solution
• Provide collaboration tools for repurposing
• Create new economic engines/incentives to support repurposing.

3. The world’s first online
collaboration platform
repurposing research
3 Potential Alternative Funding Sources
The Low Profit Pharma Company
Bringing low profit
commercializable generic drug
repurposing to market with the
support of Impact Investors
The Generic Drug
Companies Initiative
Partner with generic drug companies to
fund generic drug repurposing research
based on potential overall increases in
the sales of generic drugs.
Ongoing
Feasibilit
y
Possibility

4. Ongoing-CureAccelerator
Robert Wood Johnson Foundation provided a grant for
the development of CureAccelerator. Development
began in June 2014 and CureAccelerator version 1.0
launched in May 2015.
9 Repurposing Research projects funded through
CureAccelerator since March 2015 from 7 different
funding sources, including 2 first time funders in
medical research by participating in CureAccelerator
CureAccelerator version 2.0 is under development and
enhancements, including industry Requests for
Proposals and online scientific review.

5. By connecting researchers, funders, the biomedical industry and
patient groups, CureAccelerator will speed the pace of repurposing
research, driving more treatments more quickly to more patients.

7. Feasibility-Low Profit Pharma Company
Huge Global Problem – Too many unsolved diseases, too few
therapeutic breakthroughs, the ones that come are too slow to
get to patients and too expensive.
Solution –Generic drug repurposing can provide “new” therapies,
but often have huge financing challenges.
Innovation – create an investment vehicle for Impact Investors – a
low profit drug repurposing company to identify repurposing
opportunities across all disease classes that have potential
commercial return and patient impact, but are below industry
market returns.
Cures Within Reach is in the planning stages of this initiative. If we
can prove that it works, we can provide the framework to other
organizations and their Impact Investors.

8. Feasibility-Low Profit Pharma Company
• Start with clinical trial ready opportunities
• Validate/vet science through volunteer
SAB/MAB
• Evaluate IP/regulatory/market through pro bono
support
• Meet with FDA/EMA regulators early and often
• Complete low-cost POC clinical trials through
academia
• Use pro bono or low cost support for rest of
regulatory process
• Market through generic drug company partners

9. Possibility-The Generic Drug Companies
Repurposing Partnership
Economic Innovation – Partner with generic drug companies to
fund generic drug repurposing based on overall increases in the
sales of generic drugs.
It makes sense –Every new repurposed generic drug use would
improve healthcare outcomes and increase revenue to generic
drug companies. The short-term investment is small and the long-
term return is large. CWR can promote off-label uses even if a
drug company cannot.
Generic drug company’s information about off-label use of drugs
can inform researchers to propose additional repurposed uses.
This is a strong marketing/PR opportunity for generic drug
companies, showing their commitment to creating effective low
cost treatments for patients.

10. For more information, see
www.cureswithinreach.org
www.cureaccelerator.org
Twitter.com/CuresWReach
Facebook.com/P4Cures
Or contact:
Dr. Bruce Bloom
President and CSO
Bruce@cureswithinreach.org
847-745-1245

11. Feasibility-Social Impact Bond Initiative
Problem-Industry does not fund generic drug
repurposing for current dosage and formulation
because there is little profit potential.
Solution-Create incentive for investors to finance life-
saving Repurposing Research through a Social Impact
Bond (SIB) in which the government pays for improved
healthcare outcomes and reduced healthcare costs
through drug repurposing.
CWR is currently developing this SIB concept with the
British Government and beginning to talk with the UN
and others about a global SIB initiative

12. Feasibility-Social Impact Bond Initiative

13. Feasibility-Social Impact Bond ROI
#
of
clinical
trials
Average
cost
per
clinical
trial
Total
Rediscovery
Research
Costs
Potential
success
rate
#
of
"new"
treatments
created
#
of
patients
who
have
one
disease
with
a
"new
treatment
Projected
annual
healthcare
$
saved/average
patient
Total
potential
5
year
savings
for
all
patients
with
these
diseases
%
patients
actually
using
the
"new"
treatments
healthcare
$
saved
on
this
sub-­‐
population
of
patients
AFTER
repaying
investors
200 250,000 $50,000,000 10% 20 3000 $10,000 $600,000,000 10% $10,000,000
200 250,000 $50,000,000 15% 30 4000 $20,000 $2,400,000,000 10% $190,000,000
200 250,000 $50,000,000 20% 40 8000 $30,000 $9,600,000,000 10% $910,000,000
200 250,000 $50,000,000 25% 50 15000 $40,000 $30,000,000,000 10% $2,950,000,000
200 250,000 $50,000,000 30% 60 32000 $50,000 $96,000,000,000 10% $9,550,000,000